Regulatory delays at Malaysia facility
FDA issued a CRL for insulin aspart due to pre-approval inspection deficiencies at the Malaysia facility; resolution timeline uncertain.
high · management_commentaryBiocon Limited — Q2 FY24
Biocon's Q2 FY24 consolidated revenue from operations grew 49% YoY to INR 3,462 crore, driven by biosimilars revenue nearly doubling post-Viatris acquisition.
neutral
medium
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Slower adalimumab (Hulio) uptake in US
Market adoption of adalimumab biosimilars has been slower than anticipated, impacting Hulio's revenue contribution; management expects improvement only in 2024-25.
high · management_commentaryPricing pressure in generics API business
API business faced pricing pressure and muted offtake due to customer inventory stocking; recovery expected but uncertain.
medium · management_commentaryHigh debt and interest costs
Net debt to EBITDA elevated; interest costs rising due to high rate environment; deferred payments in FY25 may require additional funding.
medium · analyst_question